Floatz logo

CDX 1140

HER2-negative Breast Cancer

University of Texas Southwestern Medical Centermonoclonal_antibodyPhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

191 Active assets in the HER2-negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Palbociclib
Helwan University
Phase 2BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2BBB
Atezolizumab
TransThera Sciences (Nanjing), Inc.
Phase 2BB
Inno-206
Roswell Park Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

CDX 1140 is also rated in:

primary peritoneal carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
endometrial serous adenocarcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
ovarian carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →